Evidence map›Paper›PMID 27936080›Full record

ArticlePloS one2016

Effects of Pyrogallol on Growth and Cytotoxicity of Wild-Type and katG Mutant Strains of Vibrio vulnificus.

Ju Young Lim, Choon-Mee Kim, Joon Haeng Rhee, Young Ran Kim

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Antibacterial Activities of Phenolic Compounds inAntibiotics (Basel, Switzerland) · 2024
    Article
  4. Chemistry and Bioactivity ofMolecules (Basel, Switzerland) · 2022
    Article
  5. Article
  6. TargetingFrontiers in microbiology · 2021
    Article
  7. Biology · 2020
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ju Young LimCollege of Pharmacy and Research Institute of Drug Development, Chonnam National University, Chonnam National University, Gwangju, Republic of Korea.
Choon-Mee KimPremedical Sciences, Chosun University Medical School, Gwangju, Republic of Korea.
Joon Haeng RheeClinical Vaccine Research and Development Center, Department of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea.
Young Ran KimCollege of Pharmacy and Research Institute of Drug Development, Chonnam National University, Chonnam National University, Gwangju, Republic of Korea.
Chonnam National University · KRChosun University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vibrio vulnificus is a causative agent of fatal septicemia and necrotic wound infection and the pathogen infection became an important public health problem in many counties. Vibrio vulnificus causes RtxA1 toxin-induced acute cell death. We tried to identify natural products that inhibit the acute cytotoxicity of V. vulnificus using a lactate hydrogenase assay. A polyphenol pyrogallol protected HeLa cells from V. vulnificus-induced cytotoxicity. Pyrogallol also decreased the growth of V. vulnificus; this inhibitory effect was more significant during log phase than stationary phase. To further elucidate the inhibitory mechanism, pyrogallol-induced toxicity was compared between a V. vulnificus catalase-peroxidase mutant (katG-) and the isogenic wild-type MO6-24/O strains. No growth was observed for the katG- mutant in the presence of pyrogallol (50 μg/mL) even after 24 h, whereas the wild-type strain demonstrated growth recovery following a prolonged lag phase. Pyrogallol-mediated growth inhibition of the katG- mutant strain was partially rescued by exogenous catalase treatment. These results indicate that the mechanism by which pyrogallol inhibits the growth and cytotoxicity of V. vulnificus likely involves polyphenol-induced prooxidant damage. Taken together, these results suggest that pyrogallol has potential for development as a new paradigm drug to treat infectious diseases.

Indexed as

Anti-Bacterial AgentsAntioxidantsBacterial ToxinsCatalaseGene DeletionGene Expression Regulation, BacterialHeLa CellsHumansPyrogallolVibrio InfectionsVibrio vulnificusAnti-Bacterial AgentsAntioxidantsBacterial ToxinsCatalasePyrogallol

Identifiers

PMID27936080
PMCPMC5147952
OpenAlexW2560561137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.